U C B SA (UCB.BR)
41.33EUR
11:35am EDT
€0.08 (+0.18%)
€41.26
€41.26
€41.59
€41.04
190,672
280,905
€50.24
€38.01
UCB.BR
About
Overall
| Beta: | 0.56 |
| Market Cap (Mil.): | €7,536.31 |
| Shares Outstanding (Mil.): | 183.43 |
| Dividend: | 0.76 |
| Yield (%): | 1.85 |
Financials
| UCB.BR | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 33.04 | 32.01 | 32.18 |
| EPS (TTM): | 1.25 | -- | -- |
| ROI: | 3.11 | 19.61 | 18.91 |
| ROE: | 5.14 | 20.45 | 19.87 |
BRIEF-UCB announces new partnership neurology research
BRUSSELS, June 11 - UCB S.A. : * Says to collaborate with crelux and 4sc discovery to meet unmet needs in
UCB suffers as cold weather delays hay fever season
BRUSSELS, April 25 - Belgian drugmaker UCB had a difficult first quarter as cold spring weather in Europe meant fewer hay fever sufferers were buying its allergy medicines, it said on Thursday.
UCB reaches maximum 250 mln euros with retail bond sale
BRUSSELS, March 27 - Belgium-based drugmaker UCB said it has raised the maximum 250 million euros ($321.47 million) it was aiming for by selling a retail bond on the Brussels stock exchange to help refinance its debt.
BRIEF-UCB, Five Prime Therapeutics collaborate
BRUSSELS, March 19 - UCB S.A. : * UCB and Five Prime Therapeutics announce strategic discovery
UCB says had positive trial for Vimpat as monotherapy
BRUSSELS - Belgian pharmaceutical company UCB said on Tuesday its new epilepsy treatment Vimpat had produced promising results in a Phase III trial into its use without other drugs.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: GlobalData
|
$125.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
